Combination VEGFR/immune Checkpoint Inhibitor Therapy: A Promising New Treatment for Renal Cell Carcinoma

British Journal of Cancer- United Kingdom

doi 10.1038/s41416-018-0175-x

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

HLA Dependent Immune Escape Mechanisms in B-Cell Lymphomas: Implications for Immune Checkpoint Inhibitor Therapy?

OncoImmunology
OncologyAllergyImmunology
2017English

The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy

Clinical Cancer Research
Cancer ResearchOncology
2019English

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy

Case Reports in Oncological Medicine
Oncology
2017English

Characteristics and Treatment of New-Onset Arthritis After Checkpoint Inhibitor Therapy

RMD Open
RheumatologyAllergyImmunology
2018English

Targeted Therapy for Renal Cell Carcinoma

2011English

Nivolumab in Treatment of Renal Cell Carcinoma During Renal Replacement Therapy

Oncology in Clinical Practice
Oncology
2019English

Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy

Archives of Pathology and Laboratory Medicine
MedicineForensic MedicinePathologyMedical Laboratory Technology
2020English

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

Cancer Research and Treatment
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy